Dyne Therapeutics (NASDAQ:DYN) Upgraded by StockNews.com to “Hold”

Dyne Therapeutics (NASDAQ:DYN) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.

DYN has been the topic of a number of other reports. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. HC Wainwright raised their price target on Dyne Therapeutics from $48.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Morgan Stanley upped their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. raised their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a report on Monday, May 6th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $50.60.

Dyne Therapeutics Trading Up 1.8 %

Shares of NASDAQ DYN opened at $46.09 on Friday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $47.45. The stock has a market cap of $4.03 billion, a P/E ratio of -11.61 and a beta of 1.07. The business’s fifty day simple moving average is $41.49 and its 200-day simple moving average is $32.54.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities analysts forecast that Dyne Therapeutics will post -3 EPS for the current fiscal year.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,136 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $31.34, for a total transaction of $66,942.24. Following the transaction, the insider now owns 147,511 shares in the company, valued at approximately $4,622,994.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Oxana Beskrovnaya sold 2,136 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $31.34, for a total value of $66,942.24. Following the completion of the sale, the insider now owns 147,511 shares in the company, valued at $4,622,994.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares in the company, valued at approximately $3,479,624.15. The disclosure for this sale can be found here. Insiders have sold a total of 163,676 shares of company stock valued at $5,270,510 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at about $140,666,000. Janus Henderson Group PLC grew its holdings in Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after buying an additional 2,663,910 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $15,758,000. Price T Rowe Associates Inc. MD increased its position in Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after buying an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.